[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center.  Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Monoclonal Antibodies Against B-Cell Chronic Lymphocytic Leukemia (B-CLL) Tumors

The National Cancer Institute's Experimental Transplantation and Immunology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize diagnostic or therapeutic mAbs against B-CLL tumor cells.

B-cell chronic lymphocytic leukemia (B-CLL) is an incurable disease developed by more than 15,000 Americans each year. Currently, there are no therapeutic monoclonal antibodies (mAbs) that specifically recognize B-CLL tumor cells.  Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a constitutively expressed tumor-specific cell surface antigen and an ideal target for therapeutic antibodies.

This invention describes four mouse anti-human ROR1 mAbs (hybridomas designated 2A2, 2D11, 1A1, and 1A7).  All four mAbs bind specifically to the extracellular domain of human ROR1 and have good potential for therapeutic development by either humanization, conversion to chimeric mouse/human antibodies, or conjugation to a radioisotope, chemical drug or bacterial toxin.  This technology can also be used for the development of research tools for the study of ROR1 in cancer biology.
Further R&D Needed:

  • Evaluate anti-tumor activity of anti-human ROR1 mAbs in ex vivo and in vivo B-CLL models
  • Evaluate diagnostic capability of anti-human ROR1 mAbs in the detection of untreated, refractory, or relapsed B-CLL
R&D Status:
  • MAbs are being characterized and compared with respect to affinity, specificity, and epitope
  • MAbs are being used to discover other ROR1-expressing cancers
IP Status:  Research Tool.  Patent protection is not being pursued for this technology.

Value Proposition:
  • Ability to develop diagnostic or therapeutic antibodies against ROR1-expressing cancers such as B-CLL and other hematologic and solid malignancies
  • Ability to develop research tools for the study of ROR1 in cancer biology  
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov

Please reference advertisement #796

Revised 1/16/2008

This opportunity is also listed under the following categories:


TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008